Internationally recognized physician-scientist José Baselga has been named Physician-in-Chief of Memorial Hospital. He joins Memorial Sloan-Kettering from Massachusetts General Hospital.

Enzalutamide, a targeted therapy co-invented by a Memorial Sloan-Kettering investigator, has received FDA approval for the treatment of men with metastatic prostate cancer.

Memorial Sloan-Kettering investigators have found that some testicular cancers arising early in life may result from genetic changes that have not been inherited from either parent.

Eric Holland, Director of the Brain Tumor Center, is a neurosurgeon and researcher who studies the molecular changes that occur in glioblastoma and other brain tumors.

Memorial Sloan-Kettering’s trial to evaluate a new therapy for patients with beta-thalassemia is the first to receive FDA approval to treat this disease with genetically engineered cells.

A team of investigators from Memorial Sloan-Kettering has shown for the first time that tumor growth, metastasis, and chemotherapy resistance are connected to the same molecular changes inside breast cancer cells.

In the largest study of genes and smoking performed in a minority population to date, researchers have discovered a gene variant that increases a person’s risk of smoking.